Management of Hypersensitivity to Platinum- and Taxane-Based Chemotherapy: cepo Review and Clinical Recommendations

Boulanger, Jim; Boursiquot, Jean-Nicolas; Cournoyer, Ghislain; Lemieux, Julie; Masse, Marie-Soleil; Almanric, Karine; Guay, Marie‐Claude

doi:10.3747/co.21.1966

Cited by 76 publications

(87 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Indication D'une Accoutumance Aux Chimiothérapies Et Biothérunclassified

“…L'incidence des hypersensibilités aux sels de platine est de 20 %, survenant en général vers la 6 e cure [1]. Les facteurs de risque sont le retraitement après une période de rémission, l'association au taxol [1]. Les réactions croisées entre sels de platine sont possibles, plus pour les patients sensibilisés à l'oxaliplatine que ceux sensibilisés au carboplatine [2].…”

Section: Indication D'une Accoutumance Aux Chimiothérapies Et Biothérunclassified

“…réactions aux taxanes ont une incidence de 8 à 50 % selon les études, et surviennent dans les 10 premières minutes de perfusion et pour 95 % lors des deuxième cures [1]. Les facteurs de risque seraient l'atopie, l'obésité, la ménopause et l'insuffisance respiratoire.…”

Section: Indication D'une Accoutumance Aux Chimiothérapies Et Biothérunclassified

See 2 more Smart Citations

Accoutumance aux chimiothérapies et aux biothérapies

Waton

Poreaux

Barbaud

2015

Revue Française d'Allergologie

View full text Add to dashboard Cite

Section: Indication D'une Accoutumance Aux Chimiothérapies Et Biothérunclassified

See 1 more Smart Citation

Accoutumance aux chimiothérapies et aux biothérapies

Waton

Poreaux

Barbaud

2015

Revue Française d'Allergologie

View full text Add to dashboard Cite

“…Hypersensitivity reactions to paclitaxel have been attributed to Cremophor EL (polyethoxylated castor oil), its solvent, which entraps the drug in micelles keeping it in solution; this vehicle can influence both bioavailability and pharmacokinetic of paclitaxel [6][7][8]. Hypersensitivity reactions of both taxanes have been dramatically decreased using premedication with corticosteroids and H1 and H2 antihistamine [9]. Neurotoxicity (cumulative sensory peripheral neuropathy) is the most severe adverse event and the cause of dose limiting toxicity of taxanes, for which no standard treatment still exists [10].…”

Section: Introductionmentioning

confidence: 99%

Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review

Iuliis

Salerno

Taglieri

et al. 2015

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Among all analyzed genes, only CYP1B1 and ABCB1 resulted the strongest candidates to become biomarkers of clinical response to taxane therapy in breast cancer, although their utilization still remains an experimental procedure. In the future, greater studies on genetic polymorphisms should be performed in order to identify differentiating signatures for patients with higher toxicity and with resistant or responsive outcome, before the administration of taxanes.

show abstract

“…The guideline article "Management of hypersensitivity to platinum-and taxane-based chemotherapy: cepo review and clinical recommendations" in this journal for the management of hypersensitivity reactions (hsr) to this group of chemotherapy agents is useful in clinical practice 1 . Administration of H 1 and H 2 blockers in addition to steroids and reduced infusion rates are important tools for a reactive oncology patient; they are also common intermediary steps for lesser hypersensitivity reactions before desensitization protocols are used 2 .…”

mentioning

confidence: 99%

An Intermediate Step for the Management of Hypersensitivity to Platinum and Taxane Chemotherapy

Bahl

Dean

2015

Current Oncology

View full text Add to dashboard Cite

The guideline article "Management of hypersensitivity to platinum-and taxane-based chemotherapy: cepo review and clinical recommendations" in this journal for the management of hypersensitivity reactions (hsr) to this group of chemotherapy agents is useful in clinical practice 1 . Administration of H 1 and H 2 blockers in addition to steroids and reduced infusion rates are important tools for a reactive oncology patient; they are also common intermediary steps for lesser hypersensitivity reactions before desensitization protocols are used 2 . Those approaches are effective in most, but not all, patients with taxane and platinum hsr.During a taxane or platinum infusion-related hsr, antigen-stimulated mast cells release leukotrienes and prostaglandins in addition to histamine and other factors. Steroids (given preventively or as a therapeutic intervention) are thought to help reduce the production of leukotrienes and prostaglandins, among other actions. But we know from clinical practice that this intervention does not prevent all reactions. For patients in whom these usual approaches to managing hsr have failed, published reports have shown success with alternative therapies that block the pharmacologic effects of the prostaglandins and leukotrienes that are also released from mast cells that participate in the hsr 3,4 .Breslow et al. 5 reported that the use of montelukast and asa, in addition to the above traditional means, have been successful in reducing both the severity and incidence of taxane and platinum hsr. Using an hsr grading system of 0 (absent), 1 (mild), 2 (moderate), and 3 (severe), he found a reduction in hsr severity from an average grade 2.14 to an average grade 0.5 when asa and montelukast were used (p < 0.001). The biologic rationale is clear, given that montelukast blocks the leukotriene receptor and asa blocks the effects of the prostaglandins, both offering additional and complementary means to avert the other mast-cell contributions to the hsr.In our community cancer centre experience, of 375 taxane-, platinum-, and rituximab-based chemotherapy treatments given during a 6-week period (March and April 2014), 32 of the treatments resulted in hsr, prompting the use of montelukast alone or in combination with asa, concomitant to the use of additional steroids, antihistamines, and H 2 blockers. Using the Common Terminology Criteria for Adverse Events system (version 4.0) to grade the severity of reactions [0, no reaction; 1, mild; 2, moderate; 3, severe (no epinephrine); 4, severe (epinephrine required); 5, death], we found that 45% had grade 3 reactions, followed by grade 2 (36%) and grade 1 (19%) reactions. Treatments in which montelukast with or without asa was administered had significant amelioration of the hsrs, resulting in no inpatient admissions to hospital, no nursing overtime in the chemo suite, and no utilization of hypersensitivity dilution protocols for the patients. More importantly, no changes in the chemotherapy regimen protocols because of intolerance were observed, and subseq...

show abstract

Management of Hypersensitivity to Platinum- and Taxane-Based Chemotherapy: cepo Review and Clinical Recommendations

Cited by 76 publications

References 72 publications

Accoutumance aux chimiothérapies et aux biothérapies

Accoutumance aux chimiothérapies et aux biothérapies

Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review

An Intermediate Step for the Management of Hypersensitivity to Platinum and Taxane Chemotherapy

Contact Info

Product

Resources

About